Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatme...

Autores
Carpano, Marina; Perona, Marina; Rodríguez, Carla Beatriz; Nievas, Susana Isabel; Olivera, María; Santa Cruz, Gustavo Alberto; Brandizzi, Daniel; Cabrini, Romulo Luis; Pisarev, Mario Alberto; Juvenal, Guillermo Juan; Dagrosa, María Alejandra
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose: Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina (10BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. Methods and Materials: The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 106 MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. Results: The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 2.6 mg/g in tumor, with individual values ranging between 11.7 and 52.0 mg/g of 10B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37C and 23C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R2 Z 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R2 Z 0.81, logistic function fit). Conclusion: We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT treatment for each individual patient and lesion.
Fil: Carpano, Marina. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina
Fil: Perona, Marina. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Rodríguez, Carla Beatriz. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina
Fil: Nievas, Susana Isabel. Comisión Nacional de Energía Atómica; Argentina
Fil: Olivera, María. Comisión Nacional de Energía Atómica; Argentina
Fil: Santa Cruz, Gustavo Alberto. Comisión Nacional de Energía Atómica; Argentina
Fil: Brandizzi, Daniel. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina
Fil: Cabrini, Romulo Luis. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina
Fil: Pisarev, Mario Alberto. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Juvenal, Guillermo Juan. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Dagrosa, María Alejandra. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
BPA
MELANOMA
INDIVIDUAL
INFRARED IMAGING
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/111885
Acceder
id CONICETDig_8b3a484f5c5e34fd1bd639f06c754a97
oai_identifier_str oai:ri.conicet.gov.ar:11336/111885
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatmentCarpano, MarinaPerona, MarinaRodríguez, Carla BeatrizNievas, Susana IsabelOlivera, MaríaSanta Cruz, Gustavo AlbertoBrandizzi, DanielCabrini, Romulo LuisPisarev, Mario AlbertoJuvenal, Guillermo JuanDagrosa, María AlejandraBPAMELANOMAINDIVIDUALINFRARED IMAGINGhttps://purl.org/becyt/ford/3.5https://purl.org/becyt/ford/3Purpose: Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina (10BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. Methods and Materials: The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 106 MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. Results: The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 2.6 mg/g in tumor, with individual values ranging between 11.7 and 52.0 mg/g of 10B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37C and 23C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R2 Z 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R2 Z 0.81, logistic function fit). Conclusion: We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT treatment for each individual patient and lesion.Fil: Carpano, Marina. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); ArgentinaFil: Perona, Marina. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Rodríguez, Carla Beatriz. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); ArgentinaFil: Nievas, Susana Isabel. Comisión Nacional de Energía Atómica; ArgentinaFil: Olivera, María. Comisión Nacional de Energía Atómica; ArgentinaFil: Santa Cruz, Gustavo Alberto. Comisión Nacional de Energía Atómica; ArgentinaFil: Brandizzi, Daniel. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); ArgentinaFil: Cabrini, Romulo Luis. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); ArgentinaFil: Pisarev, Mario Alberto. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Juvenal, Guillermo Juan. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Dagrosa, María Alejandra. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaElsevier Science Inc2015-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/111885Carpano, Marina; Perona, Marina; Rodríguez, Carla Beatriz; Nievas, Susana Isabel; Olivera, María; et al.; Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment; Elsevier Science Inc; International Journal Of Radiation Oncology Biology Physics; 93; 2; 5-2015; 344-3520360-3016CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.redjournal.org/article/S0360-3016(15)00601-X/fulltextinfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijrobp.2015.05.039info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:05:29Zoai:ri.conicet.gov.ar:11336/111885instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:05:30.2CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment
title Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment
spellingShingle Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment
Carpano, Marina
BPA
MELANOMA
INDIVIDUAL
INFRARED IMAGING
title_short Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment
title_full Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment
title_fullStr Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment
title_full_unstemmed Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment
title_sort Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment
dc.creator.none.fl_str_mv Carpano, Marina
Perona, Marina
Rodríguez, Carla Beatriz
Nievas, Susana Isabel
Olivera, María
Santa Cruz, Gustavo Alberto
Brandizzi, Daniel
Cabrini, Romulo Luis
Pisarev, Mario Alberto
Juvenal, Guillermo Juan
Dagrosa, María Alejandra
author Carpano, Marina
author_facet Carpano, Marina
Perona, Marina
Rodríguez, Carla Beatriz
Nievas, Susana Isabel
Olivera, María
Santa Cruz, Gustavo Alberto
Brandizzi, Daniel
Cabrini, Romulo Luis
Pisarev, Mario Alberto
Juvenal, Guillermo Juan
Dagrosa, María Alejandra
author_role author
author2 Perona, Marina
Rodríguez, Carla Beatriz
Nievas, Susana Isabel
Olivera, María
Santa Cruz, Gustavo Alberto
Brandizzi, Daniel
Cabrini, Romulo Luis
Pisarev, Mario Alberto
Juvenal, Guillermo Juan
Dagrosa, María Alejandra
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BPA
MELANOMA
INDIVIDUAL
INFRARED IMAGING
topic BPA
MELANOMA
INDIVIDUAL
INFRARED IMAGING
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.5
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Purpose: Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina (10BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. Methods and Materials: The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 106 MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. Results: The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 2.6 mg/g in tumor, with individual values ranging between 11.7 and 52.0 mg/g of 10B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37C and 23C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R2 Z 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R2 Z 0.81, logistic function fit). Conclusion: We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT treatment for each individual patient and lesion.
Fil: Carpano, Marina. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina
Fil: Perona, Marina. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Rodríguez, Carla Beatriz. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina
Fil: Nievas, Susana Isabel. Comisión Nacional de Energía Atómica; Argentina
Fil: Olivera, María. Comisión Nacional de Energía Atómica; Argentina
Fil: Santa Cruz, Gustavo Alberto. Comisión Nacional de Energía Atómica; Argentina
Fil: Brandizzi, Daniel. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina
Fil: Cabrini, Romulo Luis. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina
Fil: Pisarev, Mario Alberto. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Juvenal, Guillermo Juan. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Dagrosa, María Alejandra. Comisión Nacional de Energía Atómica. Gerencia de Area de Aplicaciones de la Tecnología Nuclear. Gerencia de Radiobiología (Centro Atómico Constituyentes); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Purpose: Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina (10BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. Methods and Materials: The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 106 MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. Results: The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 2.6 mg/g in tumor, with individual values ranging between 11.7 and 52.0 mg/g of 10B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37C and 23C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R2 Z 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R2 Z 0.81, logistic function fit). Conclusion: We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT treatment for each individual patient and lesion.
publishDate 2015
dc.date.none.fl_str_mv 2015-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/111885
Carpano, Marina; Perona, Marina; Rodríguez, Carla Beatriz; Nievas, Susana Isabel; Olivera, María; et al.; Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment; Elsevier Science Inc; International Journal Of Radiation Oncology Biology Physics; 93; 2; 5-2015; 344-352
0360-3016
CONICET Digital
CONICET
url http://hdl.handle.net/11336/111885
identifier_str_mv Carpano, Marina; Perona, Marina; Rodríguez, Carla Beatriz; Nievas, Susana Isabel; Olivera, María; et al.; Experimental studies of boronophenylalanine (10BPA) biodistribution for the individually tailored application of boron neutron capture therapy (BNCT) for malignant melanoma treatment; Elsevier Science Inc; International Journal Of Radiation Oncology Biology Physics; 93; 2; 5-2015; 344-352
0360-3016
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.redjournal.org/article/S0360-3016(15)00601-X/fulltext
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijrobp.2015.05.039
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science Inc
publisher.none.fl_str_mv Elsevier Science Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613891745644544
score 13.070432

Publicaciones similares